The aim of the study is to investigate the treatment response of metformin, Peg-IFN and ribavirin combination therapy for chronic hepatitis C virus (HCV).
Current standard of treatment for HCV with pegylated interferon(Peg-IFN)-alpha and ribavirin can achieve sustained virological response (SVR) in only 60-90% of patients. Insulin resistance is an important factor of non-response to combination therapy. Metformin is a insulin sensitizer and can effectively reduce insulin resistance. The aim of the study is to investigate the treatment response of metformin, Peg-IFN and ribavirin combination therapy for chronic HCV.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
metformin 500mg tid
pegasys 180 mcg qw
ribavirin 800-1200 mg qd according to BW
Kaohsiung Veterans General Hospital
Kaohsiung, Taiwan, Taiwan
RECRUITINGsustained virological response
HCV RNA negative 24 weeks after treatment is stopped
Time frame: 24 weeks after treatment is stopped
change of HOMA-IR
Check Serial change HOMA-IR at baseline, 4 weeks and 12 weeks after treatment
Time frame: Serial change of HOMA-IR at baseline, 4 weeks and 12 weeks after treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.